These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 39101880

  • 1. Unveiling hierarchy and spatial distribution of O6-methylguanine-DNA methyltransferase promoter methylation in World Health Organization grade 2-3 gliomas.
    Li M, Liu J, Weng J, Dong G, Chen X, Cui Y, Ren X, Shen S, Jiang H, Zhang X, Zhao X, Li M, Wang X, Ren H, Li Q, Zhang Y, Cheng Q, Yu Y, Lin S.
    Cancer Sci; 2024 Oct; 115(10):3403-3414. PubMed ID: 39101880
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.
    World J Surg Oncol; 2013 Oct 25; 11():284. PubMed ID: 24160898
    [Abstract] [Full Text] [Related]

  • 3. The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory.
    Kurdi M, Alkhotani A, Sabbagh A, Faizo E, Lary AI, Bamaga AK, Almansouri M, Hafiz B, Alsharif T, Baeesa S.
    Oncol Res; 2024 Oct 25; 32(6):1037-1045. PubMed ID: 38827324
    [Abstract] [Full Text] [Related]

  • 4. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C, Azevedo A, Esteves S, Marques AR, Martins C, Costa I, Mafra M, Bravo Marques JM, Roque L, Pojo M.
    BMC Cancer; 2019 Oct 17; 19(1):968. PubMed ID: 31623593
    [Abstract] [Full Text] [Related]

  • 5. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
    Arita H, Matsushita Y, Machida R, Yamasaki K, Hata N, Ohno M, Yamaguchi S, Sasayama T, Tanaka S, Higuchi F, Iuchi T, Saito K, Kanamori M, Matsuda KI, Miyake Y, Tamura K, Tamai S, Nakamura T, Uda T, Okita Y, Fukai J, Sakamoto D, Hattori Y, Pareira ES, Hatae R, Ishi Y, Miyakita Y, Tanaka K, Takayanagi S, Otani R, Sakaida T, Kobayashi K, Saito R, Kurozumi K, Shofuda T, Nonaka M, Suzuki H, Shibuya M, Komori T, Sasaki H, Mizoguchi M, Kishima H, Nakada M, Sonoda Y, Tominaga T, Nagane M, Nishikawa R, Kanemura Y, Kuchiba A, Narita Y, Ichimura K.
    Acta Neuropathol Commun; 2020 Nov 23; 8(1):201. PubMed ID: 33228806
    [Abstract] [Full Text] [Related]

  • 6. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
    Wiestler B, Capper D, Hovestadt V, Sill M, Jones DT, Hartmann C, Felsberg J, Platten M, Feiden W, Keyvani K, Pfister SM, Wiestler OD, Meyermann R, Reifenberger G, Pietsch T, von Deimling A, Weller M, Wick W.
    Neuro Oncol; 2014 Dec 23; 16(12):1630-8. PubMed ID: 25028501
    [Abstract] [Full Text] [Related]

  • 7. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.
    Kinslow CJ, Mercurio A, Kumar P, Rae AI, Siegelin MD, Grinband J, Taparra K, Upadhyayula PS, McKhann GM, Sisti MB, Bruce JN, Canoll PD, Iwamoto FM, Kachnic LA, Yu JB, Cheng SK, Wang TJC.
    JAMA Oncol; 2023 Jul 01; 9(7):919-927. PubMed ID: 37200021
    [Abstract] [Full Text] [Related]

  • 8. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
    Yi L, Fan X, Li J, Yuan F, Zhao J, Nistér M, Yang X.
    Aging (Albany NY); 2021 Jan 20; 13(3):3645-3660. PubMed ID: 33493139
    [Abstract] [Full Text] [Related]

  • 9. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
    Li MY, Wang YY, Cai JQ, Zhang CB, Wang KY, Cheng W, Liu YW, Zhang W, Jiang T.
    PLoS One; 2015 Jan 20; 10(6):e0130872. PubMed ID: 26115094
    [Abstract] [Full Text] [Related]

  • 10. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
    Juratli TA, Lautenschläger T, Geiger KD, Pinzer T, Krause M, Schackert G, Krex D.
    J Neurooncol; 2015 Sep 20; 124(2):197-205. PubMed ID: 26033545
    [Abstract] [Full Text] [Related]

  • 11. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M, Drábek J, Dwight Z, Trojanec R, Koudeláková V, Vrbková J, Kalita O, Mlcochova S, Rabcanova M, Hajdúch M.
    Klin Onkol; 2017 Sep 20; 30(5):361-371. PubMed ID: 29031038
    [Abstract] [Full Text] [Related]

  • 12. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
    Park YW, Kim S, Han K, Ahn SS, Moon JH, Kim EH, Kim J, Kang SG, Kim SH, Lee SK, Chang JH.
    Eur Radiol; 2024 Feb 20; 34(2):1376-1387. PubMed ID: 37608093
    [Abstract] [Full Text] [Related]

  • 13. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J, Yang JH, Quan J, Kang X, Wang HJ, Dai PG.
    Tumour Biol; 2016 Oct 20; 37(10):13571-13579. PubMed ID: 27468718
    [Abstract] [Full Text] [Related]

  • 14. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T.
    Neuro Oncol; 2012 Jan 20; 14(1):109-16. PubMed ID: 22039037
    [Abstract] [Full Text] [Related]

  • 15. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS, Kwon MJ, Song JH, Kim ES, Kim HY, Min KW.
    Pathol Res Pract; 2018 Jun 20; 214(6):881-888. PubMed ID: 29650441
    [Abstract] [Full Text] [Related]

  • 16. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
    Ochsenbein AF, Schubert AD, Vassella E, Mariani L.
    J Neurooncol; 2011 Jun 20; 103(2):343-51. PubMed ID: 20857319
    [Abstract] [Full Text] [Related]

  • 17. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M.
    Neurology; 2013 Oct 22; 81(17):1515-22. PubMed ID: 24068788
    [Abstract] [Full Text] [Related]

  • 18. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.
    Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.
    J Neurooncol; 2012 May 22; 107(3):617-31. PubMed ID: 22287028
    [Abstract] [Full Text] [Related]

  • 19. Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.
    Huang L, Jiang T, Yuan F, Li GL, Cui Y, Liu EZ, Wang ZC.
    Neuropathol Appl Neurobiol; 2009 Aug 22; 35(4):367-379. PubMed ID: 19019173
    [Abstract] [Full Text] [Related]

  • 20. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T, Sonoda Y, Shibahara I, Saito R, Kanamori M, Kumabe T, Tominaga T.
    J Neurooncol; 2016 Sep 22; 129(3):505-514. PubMed ID: 27401154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.